Approval is supported by data from the DEVOTE study which showed the benefit of the SPINRAZA 50 mg and 28 mg regimen in both ...
A single dose of either bivalent or nonvalent HPV vaccine was just as protective as the standard two doses of either vaccine ...
Ocugen has announced positive preliminary 12-month data from its phase 2 ArMaDa trial evaluating OCU410 (AAV5-RORA) for the ...
A single dose of intravenous (IV) iron dextran is the cost-effective treatment for women with heavy menstrual bleeding and ...
The optimal hydroxychloroquine blood level in lupus is between 750 ng/mL and 1,150 ng/mL, which can help prevent active ...
Intravenous (IV) iron therapy is more effective than oral drugs for women with anemia and heavy periods, providing better ...
The United States Patent and Trademark Office has issued U.S. Patent No. 12,514,854 B2, an Orange Book-listable patent ...
The Company’s abstract, Evaluation of Teverelix in Healthy Female Volunteers, has been accepted for presentation at American ...
Ocugen, Inc. gene therapy outlook: key 2026 catalysts, Phase 2/3 eye-disease data, BLA plans to 2028, and risks. Click for ...
Phase 2 (~50% of patients evaluated to date at 12 months) shows 46% lesion growth reduction vs. controlThere are no OCU410-related serious ...
SECuRE trial to continue with no modifications to protocol following Safety Review Committee meeting
HIGHLIGHTSFollowing an interim data review of the Cohort Expansion Phase (Phase II) of the SECuRE trial, the Safety Review ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback